Targeting Fusions and Rearrangements in Solid Tumors
Targeting Fusions and Rearrangements in Solid Tumors is organized by Prime Education, LLC.
Release Date: May 3, 2023
Expiration Date: May 2, 2024
Description:
Ever-increasing indications for targeted therapies have provided more and more options for solid tumor patients, making it increasingly crucial to stay on top of the latest indication updates, guidelines, and clinical data. Join us for the latest video activity in our Precision Oncology Accelerator Hub for an expert discussion on fusion and rearrangement biomarker testing, evaluation of molecular testing results, and matching patients to targeted therapies using the latest evidence.
Agenda:
• Overview of Molecular Testing for Fusions and Rearrangements in Solid Tumors: ALK, ROS1, NTRK, RET, MET, and FGFR
• Indications for Therapies Targeting Fusions and Rearrangements Based on Tumor Type, Stage, and Biomarker Status
LEARNING OBJECTIVES
• Identify frequent biomarkers across solid tumors and understand appropriate timing of testing to detect these biomarkers
• Interpret results of next-generation sequencing and other testing methodologies to identify biomarkers predictive of response to immunotherapies and targeted therapies
• Develop targeted treatment strategies for treatment of solid tumors
• Differentiate novel targeted therapies and immunotherapies in solid tumors based on biomarkers, approved indications, safety, and efficacy.